Rapid News Brief: Ingersoll Rand outlined its purchase of IVEK on Nov. 2, adding precision liquid metering and dispensing equipment to its life sciences business. The acquisition brings a specialized component supplier into a larger industrial portfolio, rather than marking a newly announced drug or medical treatment.
The company said IVEK contributes approximately $40 million in annual revenue and will join the Life Sciences platform within its Precision and Science Technologies segment. Ingersoll Rand described the purchase multiple as being in the low double digits relative to IVEK’s 2025 adjusted earnings before interest, taxes, depreciation and amortization, before synergies.
Small-volume fluid control
IVEK makes systems that measure and dispense small amounts of liquid. Its website describes applications in laboratories, diagnostics, pharmaceutical production and biotechnology instrumentation. These are equipment capabilities, not evidence of improved clinical outcomes from the acquisition.
The company’s product range includes single-channel dispensing, multichannel systems and liquid metering equipment. It also supplies components to original equipment manufacturers and integrators, making its commercial role broader than selling standalone machines.
IVEK describes ceramic pump heads, motor drives and electronic controls as central elements of its systems. Its application-testing service is intended to match fluid-handling equipment to a customer’s requirements. Those details help explain why engineering expertise and integration capabilities matter alongside production capacity in this business.
A previously disclosed closing
The Nov. 2 release provides acquisition details, but the transaction was already discussed on Ingersoll Rand’s Oct. 30 earnings call. According to the published transcript, CEO Vicente Reynal said the company had closed the purchase that morning. The later release should not be mistaken for evidence that the deal first closed Nov. 2.
Ingersoll Rand’s stated rationale is to broaden its precision-pump offering for life sciences customers. The annual revenue figure describes the acquired business; it is not a newly signed customer order or a forecast of incremental profit.
The operational test will be how the business fits into the buyer’s product and service network. The announcement does not quantify completed cost savings, establish a customer migration schedule or demonstrate that anticipated integration benefits have already been realized.